172 related articles for article (PubMed ID: 15572384)
1. Development and validation of an immunosuppressant therapy adherence barrier instrument.
Chisholm MA; Lance CE; Williamson GM; Mulloy LL
Nephrol Dial Transplant; 2005 Jan; 20(1):181-8. PubMed ID: 15572384
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of the immunosuppressant therapy adherence instrument (ITAS).
Chisholm MA; Lance CE; Williamson GM; Mulloy LL
Patient Educ Couns; 2005 Oct; 59(1):13-20. PubMed ID: 16198214
[TBL] [Abstract][Full Text] [Related]
3. Psychometric re-evaluation of the immunosuppressant therapy adherence scale among solid-organ transplant recipients.
Wilks SE; Spivey CA; Chisholm-Burns MA
J Eval Clin Pract; 2010 Feb; 16(1):64-8. PubMed ID: 20367816
[TBL] [Abstract][Full Text] [Related]
4. Predicting adherence to immunosuppressant therapy: a prospective analysis of the theory of planned behaviour.
Chisholm MA; Williamson GM; Lance CE; Mulloy LL
Nephrol Dial Transplant; 2007 Aug; 22(8):2339-48. PubMed ID: 17442741
[TBL] [Abstract][Full Text] [Related]
5. Derivation and validation of the ASK-12 adherence barrier survey.
Matza LS; Park J; Coyne KS; Skinner EP; Malley KG; Wolever RQ
Ann Pharmacother; 2009 Oct; 43(10):1621-30. PubMed ID: 19776298
[TBL] [Abstract][Full Text] [Related]
6. Developing and testing an instrument for identifying culture-specific barriers to breast cancer screening in Israeli Arab women.
Cohen M; Azaiza F
Acta Oncol; 2008; 47(8):1570-7. PubMed ID: 18607884
[TBL] [Abstract][Full Text] [Related]
7. Studying the Hurdles of Insulin Prescription (SHIP): development, scoring and initial validation of a new self-administered questionnaire.
Martinez L; Consoli SM; Monnier L; Simon D; Wong O; Yomtov B; Guéron B; Benmedjahed K; Guillemin I; Arnould B
Health Qual Life Outcomes; 2007 Aug; 5():53. PubMed ID: 17727695
[TBL] [Abstract][Full Text] [Related]
8. Identifying barriers to medication adherence in adolescent transplant recipients.
Simons LE; Blount RL
J Pediatr Psychol; 2007 Aug; 32(7):831-44. PubMed ID: 17522111
[TBL] [Abstract][Full Text] [Related]
9. Effectively measuring adherence to medications for systemic lupus erythematosus in a clinical setting.
Koneru S; Shishov M; Ware A; Farhey Y; Mongey AB; Graham TB; Passo MH; Houk JL; Higgins GC; Brunner HI
Arthritis Rheum; 2007 Aug; 57(6):1000-6. PubMed ID: 17665465
[TBL] [Abstract][Full Text] [Related]
10. Perceived barriers to adherence among adolescent renal transplant candidates.
Zelikovsky N; Schast AP; Palmer J; Meyers KE
Pediatr Transplant; 2008 May; 12(3):300-8. PubMed ID: 18194352
[TBL] [Abstract][Full Text] [Related]
11. Rurality and other factors associated with adherence to immunosuppressant medications in community-dwelling solid-organ transplant recipients.
Sankaranarayanan J; Collier D; Furasek A; Reardon T; Smith LM; McCartan M; Langnas AN
Res Social Adm Pharm; 2012; 8(3):228-39. PubMed ID: 21856247
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation.
Heinze G; Mitterbauer C; Regele H; Kramar R; Winkelmayer WC; Curhan GC; Oberbauer R
J Am Soc Nephrol; 2006 Mar; 17(3):889-99. PubMed ID: 16481415
[TBL] [Abstract][Full Text] [Related]
13. Comparing renal transplant patients' adherence to free cyclosporine and free tacrolimus immunosuppressant therapy.
Chisholm MA; Mulloy LL; DiPiro JT
Clin Transplant; 2005 Feb; 19(1):77-82. PubMed ID: 15659138
[TBL] [Abstract][Full Text] [Related]
14. Satisfaction and adherence with immunosuppressant treatment in renal transplant patients living with a working graft.
Ortega F; Otero A; Crespo JF; Delgado JF; Borro JM; Cuervo J;
J Nephrol; 2013; 26(2):297-305. PubMed ID: 22684646
[TBL] [Abstract][Full Text] [Related]
15. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
[TBL] [Abstract][Full Text] [Related]
16. Determining the effect of immunosuppressant adherence on graft failure risk among renal transplant recipients.
Spivey CA; Chisholm-Burns MA; Damadzadeh B; Billheimer D
Clin Transplant; 2014 Jan; 28(1):96-104. PubMed ID: 24329814
[TBL] [Abstract][Full Text] [Related]
17. Immunosuppressant treatment adherence, barriers to adherence and quality of life in renal and liver transplant recipients in Spain.
Morales JM; Varo E; Lázaro P
Clin Transplant; 2012; 26(2):369-76. PubMed ID: 22035067
[TBL] [Abstract][Full Text] [Related]
18. Patient factors associated with adherence to immunosuppressant therapy in renal transplant recipients.
Chisholm MA; Lance CE; Mulloy LL
Am J Health Syst Pharm; 2005 Sep; 62(17):1775-81. PubMed ID: 16120736
[TBL] [Abstract][Full Text] [Related]
19. Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases.
Büchler M; Chadban S; Cole E; Midtvedt K; Thervet E; Prestele H; Keown P
Nephrol Dial Transplant; 2006 Jan; 21(1):197-202. PubMed ID: 16204301
[TBL] [Abstract][Full Text] [Related]
20. Treatment adherence in renal transplant recipients: a questionnaire survey on immunosuppressants.
Ichimaru N; Kakuta Y; Abe T; Okumi M; Imamura R; Isaka Y; Nonomura N; Kojima Y; Okuyama A; Takahara S
Transplant Proc; 2008 Jun; 40(5):1362-5. PubMed ID: 18589106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
